SCHEMBL4475222

SCHEMBL4475222

CC1(C)C=Cc2cc(CC(=O)NCc3ccc(Cl)cc3)ccc2O1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.51
▸ KMT2A Q03164 3/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ HIF1A Q16665 10/20 0.49
▸ EPAS1 Q99814 9/20 0.49
▸ ERCC1 P07992 1/20 0.46
▸ ERCC4 Q92889 1/20 0.46
▸ POLB P06746 1/20 0.44
▸ CA12 O43570 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ CA9 Q16790 1/20 0.44
▸ P2RX7 Q99572 1/20 0.44
▸ HPGD P15428 1/20 0.42
▸ COXFA4 O00483 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4484899 0.90 HIF1A (0.52) ALDH1A1NPC1RAB9AHIF1AEPAS1
SCHEMBL4471596 0.81 HPGD (0.50) ALDH1A1HIF1AEPAS1CA1CA2
SCHEMBL2825117 0.78 HIF1A (0.52) ALDH1A1HIF1AEPAS1HPGDCOXFA4
SCHEMBL2827569 0.77 HIF1A (0.54) HIF1AEPAS1COXFA4
SCHEMBL4481443 0.73 MEN1 (0.48) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL4474217 0.73 MEN1 (0.48) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL4479165 0.73 MEN1 (0.48) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL9219622 0.72 HTR2C (0.54) ALDH1A1NPC1RAB9AHIF1AEPAS1
SCHEMBL16082991 0.72 ALDH1A1 (0.83) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL14930293 0.72 HIF1A (0.61) HIF1AEPAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534903-B2 Use of amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl-compounds in the treatment of cardiac arrhythmia and other disease states SOLVAY PHARMACEUTICALS GMBH (DE) 2009-05-19 — — US disclosed
EP-1678130-B1 AMIDOMETHYL-SUBSTITUTED 2-(4-SULFONILAMINO)-3-HIDROXY-3,4-DIHYDRO-2H-CHROMIUM-6-YL-DERIVATIVES AND DRUGS CONTAINING SAID COMPOUNDS SOLVAY PHARM GMBH (DE) 2008-08-20 — — EP disclosed
US-20080113999-A1 Use of Amidomethyl-Substituted 2-(4-Sulfonylamino)-3-Hydroxy-3,4-Dihydro-2H-Chromen-6-yl-Compounds in the Treatment of Cardiac Arrhythmia and Other Disease States SOLVAY PHARMACEUTICALS GMBH (DE) 2008-05-15 — — US disclosed
US-7368582-B2 Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them SOLVAY PHARMACEUTICALS GMBH (DE) 2008-05-06 — — US disclosed
US-20050148659-A1 Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them SOLVAY PHARMACEUTICALS GMBH (DE) 2005-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148659-A1 Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP4B1, CYP3A4 MEN1 1152/4885KMT2A 2418/4885ALDH1A1 1020/4885
US-20080113999-A1 Use of Amidomethyl-Substituted 2-(4-Sulfonylamino)-3-Hydroxy-3,4-Dihydro-2H-Chromen-6-yl-Compounds in the Treatment of Cardiac Arrhythmia and Other Disease States KCNH1, RYR2, KCNJ2 MEN1 1084/4885KMT2A 1633/4885ALDH1A1 518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback